Antiparkinsonian pergolide (Permax): sudden sleep attacks
- The association of dopamine agonists with daytime sleepiness, sleep problems and quality of life in patients with Parkinson's disease: — A prospective study —. Happe, Svenja; Berger, Klaus // Journal of Neurology;Dec2001, Vol. 248 Issue 12, p1062
Objective Reports that dopamine agonists (DA) precipitate sudden daytime sleep episodes in Parkinson's disease (PD) patients have received widespread attention. It remains unclear if non-ergoline and ergoline DAs have differential sedating effects or if sedation rather represents a class effect...
- The initial drug treatment of older patients with Parkinson's disease--consider an agonist, but don't demonise dopa. MacMahon, Douglas G. // Age & Ageing;May2003, Vol. 32 Issue 3, p244
Editorial. Discusses the initial drug treatment of older patients with Parkinson's disease. Findings on the dopaminergic agonist monotherapy and other synthetic agonists; Factors to consider when deciding for the treatment of older patients with Parkinson; Life expectancy of a Parkinson patient.
- Parkinson's disease. // Age & Ageing;May2013 Supplement, Vol. 42 Issue suppl_2, pii28
The article presents an abstract on the topic of Parkinson's disease (PD) which includes the comparison of patient-rated treatment response with measured improvement in PD.
- Frequency of New-Onset Pathologic Compulsive Gambling or Hypersexuality After Drug Treatment of Idiopathic Parkinson Disease. Michael^Bostwick, J.; Hecksel, Kathleen A.; Stevens, Susanna R.; Bower, James H.; Ahlskog, J. Eric // Mayo Clinic Proceedings;Apr2009, Vol. 84 Issue 4, p310
OBJECTIVE: To determine the frequency of new-onset compulsive gambling or hypersexuality among regional patients with Parkinson disease (PD), ascertaining the relationship of these behaviors to PD drug use. PATIENTS AND METHODS: We retrospectively reviewed the medical records of patients from 7...
- Observations on Sleep-Disordered Breathing in Idiopathic Parkinsonâ€™s Disease. Valko, Philipp O.; Hauser, Sabrina; Sommerauer, Michael; Werth, Esther; Baumann, Christian R. // PLoS ONE;Jun2014, Vol. 9 Issue 6, p1
Background: This study has two main goals: 1.) to determine the potential influence of dopaminergic drugs on sleep-disordered breathing (SDB) in Parkinsonâ€™s disease (PD) and 2.) to elucidate whether NREM and REM sleep differentially impact SDB severity in PD. Methods: Retrospective...
- Factores asociados con la selecciÃ³n de pramipexol de liberaciÃ³n prolongada versus liberaciÃ³n inmediata en pacientes con enfermedad de Parkinson. Cervantes-Arriaga, Amin; Rodríguez-Violante, Mayela; López-Ruiz, Minerva; Estrada-Bellmann, Ingrid; Zúñiga-Ramírez, Carlos; Otero-Cerdeira, Elisa; Camacho-Ordóñez, Azyadeh; González-Latapi, Paulina; Morales-Briceño, Hugo; Martínez-Ramírez, Daniel // Revista Mexicana de Neurociencia;Mar/Apr2013, Vol. 14 Issue 2, p76
Introduction: Pramipexole is a dopamine agonist effective to treat the motor symptoms of Parkinson disease available as immediate or extended release. Objective: The aim of this study is to determine whether there are differences in the profile of patients receiving pramipexole according to the...
- Drugs for Parkinson's Disease Linked to Excessive Sleepiness. // Nutrition Health Review: The Consumer's Medical Journal;2001, Issue 82, p13
Investigates the association of dopamine agonists with excessive sleepiness of patients with Parkinson's disease in Canada. Properties of the dopamine agonists; Correlation of general sleepiness with episode of sleeping at the wheel; Common name of dopamine agonists, pramipexole and ropinirole.
- Emerging Therapies in the Pharmacological Treatment of Parkinson’s Disease. Korczyn, A.D.; Nussbaum, M. // Drugs;2002, Vol. 62 Issue 5, p775
The pharmacological management of Parkinsonâ€™s disease is a complex and dynamic task; there is no one â€˜rightâ€™ strategy indicating which drugs should be used at a particular stage of the disease. There are now many different drugs belonging to several classes that may be...
- WHEN INITIAL TREATMENT BEGINS TO FAILâ€¦. Mari, Zoltan // Johns Hopkins Advanced Studies in Medicine;12/10/2008, Vol. 8 Issue 12, p423
Most clinicians today consider dopamine agonist therapy as the treatment of choice for initial therapy in young patients with Parkinson's disease (PD), where such medications are tolerated and not otherwise contraindicated. However, as PD progresses, limitations to agonist therapy are often...